Erasca, Inc. (ERAS) FY2025 10-K Annual Report
Erasca, Inc. (ERAS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Erasca, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Precision oncology company focused exclusively on discovering and developing therapies targeting RAS/MAPK pathway-driven cancers
- • New emphasis: Clinical-stage programs ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) initiated INDs May 2025, first clinical data expected H1/H2 2026
- • Strategic shift: Termination of Novartis naporafenib license in June 2026 to prioritize differentiated RAS-targeting franchise development
- • Quantitative metric: Addressing ~2.7 million annual global patients with RAS-mutant tumors, including over 2.2 million with KRAS mutations targeted by ERAS-4001
- • Noteworthy fact: ERAS-0015 shows 8-21x higher cyclophilin A affinity and 5x more potent RAS inhibition preclinically versus leading competitor molecular glue
Management Discussion & Analysis
- • No revenue generated; net loss $124.5M in 2025 vs $161.7M in 2024, improving by $37.1M
- • Operating expenses down to $140.9M in 2025 from $179.6M in 2024; R&D expense 22% lower at $92.9M vs $115.4M
- • Best segment: ERAS-0015 R&D expense up to $26.9M from $6.7M; worst segment other clinical programs down from $58.3M to $32.8M
- • Cash and equivalents $341.8M as of Dec 31, 2025; raised $242.7M net in Jan 2026 offering; $150M payment to Joyo in March 2026
- • Expect Phase 1 data readouts 1H 2026 for ERAS-0015 and ERAS-4001; anticipate increased R&D and G&A expenses; cash sufficient through 2H 2028
Risk Factors
- • Regulatory risk from compliance with EU Clinical Trials Regulation (CTR) effective January 31, 2025 impacting multi-center trial approvals
- • Geopolitical risk from potential delays and cost increases due to evolving U.S. tariff and import/export regulations affecting operations
- • Operational risk in dependency on third-party contract manufacturing organizations (CMOs) for clinical and potential commercial product supply
- • Competitive risk from rapid technological advances in biopharma potentially rendering Erasca's RAS/MAPK pathway approach obsolete
- • Financial risk with $892.2M accumulated deficit and need for substantial capital beyond $242.7M raised in 2026 offering to fund operations into second half 2028
Erasca, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$125M
▲ +23.0% YoY
ROE
-38.3%
▼ -13bp YoY
Total Assets
$396M
▼ -21.2% YoY
EPS (Diluted)
$-0.44
▲ +36.2% YoY
Operating Cash Flow
-$95M
▲ +12.8% YoY
Source: XBRL data from Erasca, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Erasca, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.